staurosporine has been researched along with Leukemia, Myeloid, Acute in 187 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (2.67) | 18.2507 |
| 2000's | 28 (14.97) | 29.6817 |
| 2010's | 94 (50.27) | 24.3611 |
| 2020's | 60 (32.09) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, PT; Chen, GS; Chern, JW; Jagtap, AD; Kondekar, NB; Liu, JR; Shen, LJ; Tseng, HW; Wang, HC | 1 |
| Chen, Z; Li, H; Lyu, J; Song, W; Sun, D; Xu, Y; Yang, Y; Zhao, Z; Zhou, W | 1 |
| Chiewchanvit, S; Chuamanochan, M; Jamjanya, S; Mahanupab, P; Rattanathammethee, T; Tovanabutra, N | 1 |
| Abe, R; Maekawa, Y; Murata, T; Nishida, T; Niwa, M; Obata, Y; Okamoto, K; Shiina, I; Shimonaka, M; Suzuki, T; Tateyama, S; Yamawaki, K | 1 |
| Arnán Sangerman, M; Del Mar Tormo Díaz, M; Fernández Moreno, A; García Quintana, A; García-Vidal, C; Olave Rubio, MT; Rodriguez Macias, G; Vendranas, M | 1 |
| Ahmed, F; Ceckova, M; Sorf, A; Sucha, S; Svoren, M; Vagiannis, D; Visek, B | 1 |
| Benner, A; Bullinger, L; Döhner, H; Döhner, K; Fiedler, W; Fransecky, L; Gaidzik, VI; Ganser, A; Götze, K; Hertenstein, B; Heuser, M; Krzykalla, J; Kühn, MWM; Larson, R; Lübbert, M; Machherndl-Spandl, S; Mayer, K; Paschka, P; Ringhoffer, M; Saadati, M; Salih, H; Salwender, H; Schlenk, RF; Schrade, A; Schroeder, T; Stone, R; Theis, F; Thol, F; Tischler, HJ; Weber, D; Westermann, J; Wulf, G | 1 |
| Han, Y; He, S; Li, J; Pang, Y; Yu, L; Zhang, M; Zhao, W | 1 |
| Altman, JK; Chou, WC; Groß-Langenhoff, M; Hasabou, N; Hosono, N; Lee, JH; Levis, MJ; Lu, Q; Martinelli, G; Montesinos, P; Panoskaltsis, N; Perl, AE; Podoltsev, N; Recher, C; Röllig, C; Smith, CC; Strickland, S; Tiu, RV; Yokoyama, H | 1 |
| Grosch, K; Ouatas, T; Pathak, D; Sechaud, R; Sinclair, K | 1 |
| Cai, X; Lu, H; Sheng, Y; Weng, XQ; Wu, J; Xi, HM | 1 |
| de Leeuw, DC; Donker, ML; Franssen, LE; Schutte, T; Smits, MM; Stege, CAM | 1 |
| Aquilino, A; Barbieri, E; Barozzi, P; Bettelli, F; Bevini, M; Bresciani, P; Cassanelli, L; Ceccherelli, G; Colaci, E; Colasante, C; Comoli, P; Cordella, S; Cuoghi, A; Forghieri, F; Gilioli, A; Giusti, D; Luppi, M; Maffei, R; Malavolti, R; Manfredini, R; Marasca, R; Martinelli, S; Messerotti, A; Morselli, M; Nasillo, V; Paolini, A; Parisotto, A; Pioli, V; Potenza, L; Pozzi, S; Repaci, G; Riva, G; Tagliafico, E; Trenti, T; Venturelli, D | 1 |
| Banos, A; Béné, MC; Bérard, E; Bertoli, S; Bonmati, C; Carre, M; Chantepie, S; Chebrek, S; Chretien, ML; Cluzeau, T; Debarri, H; Desbrosses, Y; Dombret, H; Dumas, PY; Frayfer, J; Gehlkopf, E; Guièze, R; Guillerm, G; Haiat, S; Heiblig, M; Himberlin, C; Hospital, MA; Jourdan, E; Lambert, J; Laribi, K; Marcais, A; Marchand, T; Mineur, A; Orvain, C; Pasquier, F; Pautas, C; Peterlin, P; Pigneux, A; Raffoux, E; Récher, C; Santagostino, A; Tavernier, E; Turlure, P; Uzunov, M; Vaida, I; Villate, A; Wemeau, M | 1 |
| Avigdor, A; Canaani, J; Gueta, I; Loebstein, R; Marcu-Malina, V; Shimoni, A | 1 |
| Čerňan, M; Ježíšková, I; Kabut, T; Mayer, J; Podstavková, N; Semerád, L; Szotkowski, T; Weinbergerová, B | 1 |
| Cenin, DA; Donald Harvey Iii, R; Kovacsovics, T; Kurish, HP; Lee, JS; Li, BKT; Lo, M; Patel, S; Prelewicz, S; Schlafer, D; Wagner, CB; Walchack, R; Wasef, B; Ying, J | 1 |
| Brandts, C; Bug, G; Cremer, A; Cremer, S; Enssle, JC; Kouidri, K; Lang, F; Pfaff, S; Serve, H; Steffen, B; Zeiher, A | 1 |
| Bengoudifa, BR; Caillot, D; Cluzeau, T; Farkas, F; Gilotti, G; Griskevicius, L; Hodzic, S; Legrand, O; Luppi, M; Minotti, C; Montesinos, P; Rambaldi, A; Sierra, J; Thomas, X; Venditti, A | 1 |
| Levis, MJ | 1 |
| Apel, A; Aviram, A; Berger, T; Frisch, A; Hellmann, I; Koren-Michowitz, M; Moshe, Y; Ofran, Y; Raanani, P; Ram, R; Rozovski, U; Wolach, O; Yaari, S; Yeshurun, M | 1 |
| Perl, AE | 2 |
| Thol, F | 1 |
| Alshamleh, I; Günther, UL; Krause, N; Kurrle, N; Richter, C; Schwalbe, H; Serve, H | 1 |
| Coleman, M; Fechter, L; Galinsky, I | 1 |
| Chua, CC; Droogleever, MP; Fong, CY; Grigg, A; Lim, A; Schwarer, A; Singh, J; Ting, SB; Tiong, IS; Wei, AH; Zhang, L | 1 |
| Au, T; Biskupiak, J; Bonifacio, G; Brixner, D; Joseph, G; Kovacsovics, T; Menon, J; Ndife, B; Shami, PJ; Stein, E; Stenehjem, D; Tantravahi, S; Unni, S; Willis, C; Yoo, M | 1 |
| DiNardo, CD; Wei, AH | 1 |
| Wang, ES | 1 |
| Rowe, JM | 1 |
| Smith, CC | 1 |
| Arenas, A; Ayala, R; Castro, N; Gallardo, M; Gómez-López, G; Leivas, A; Linares, M; Martínez-López, J; Morales, ML; Ortiz-Ruiz, A; Quintela-Fandino, M; Rapado, I; Rodríguez-García, A; Zagorac, I | 1 |
| Arries, CD; Yohe, SL | 1 |
| Ojha, S; Ooi, MG | 1 |
| Emadi, A; Estey, E; Gale, RP; Karp, JE; Othus, M | 1 |
| Antar, AI; Bazarbachi, A; Jabbour, E; Mohty, M; Otrock, ZK | 1 |
| Daver, NG; Glass, WF; Kala, J; Pankow, JD; Richard-Carpentier, G | 1 |
| Andrieux, G; Boerries, M; Charlet, A; Duyster, J; Endres, C; Follo, M; Herchenbach, D; Keye, P; Rassner, M; Salzer, U; von Bubnoff, N; Waldeck, S | 1 |
| Adamia, S; Buhrlage, SJ; Case, AE; Gokhale, PC; Gray, N; Griffin, JD; Liu, X; Meng, C; Sattler, M; Stone, R; Tiv, HL; Wang, J; Weisberg, E; Yang, J | 1 |
| Blanc, AS; Brandt, P; Cariou, C; Dolph, M; Forsythe, A; Recher, C; Tremblay, G | 1 |
| Cooper, BW; Craig, MD; Gallogly, MM; Kane, DM; Lazarus, HM; Levis, MJ; Metheny, L; Tomlinson, BK; William, BM | 1 |
| Lam, SSY; Leung, AYH | 1 |
| Carraway, HE; Chandhok, NS; Griffiths, EA; Prebet, T | 1 |
| Bolstad, B; Dahlseng Håkonsen, G; Dalhus, M; Gisselbrecht, C; Hennik, P; Herberts, C; Kaasboll, T; Meulendijks, D; Pignatti, F; Salmonson, T; Tzogani, K; Verheijen, R; Wangen, T; Yu, Y | 1 |
| Cornely, OA; Koehler, P; Maurer, C; Müller, C; Stemler, J | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Naoe, T | 1 |
| Ballesta-López, O; Martínez-Cuadrón, D; Megías-Vericat, JE; Montesinos, P; Solana-Altabella, A | 1 |
| Andrews, C; Lam, W; Sibai, H | 1 |
| Barbera, A; Bonifacio, G; Dalovisio, A; Haines, K; Litzow, MR; Perl, AE; Purkayastha, D; Roboz, GJ; Strickland, SA; Sweet, K | 1 |
| Estey, EH | 1 |
| Berger, T; Frisch, A; Gal-Rabinovich, K; Ganzel, C; Hellmann, I; Henig, I; Horesh, N; Leiba, R; Moshe, Y; Neaman, M; Ofran, Y; Weinstein, V; Wolach, O; Yehudai-Ofir, D | 1 |
| Albors Ferreiro, M; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Mosquera Orgueira, A; Mosquera Torre, A; Peleteiro Raíndo, A; Pérez Encinas, MM | 1 |
| Abdul-Hamil, NA; Cherchione, C; Martinelli, G; Nagarajan, C; Wong, GC | 1 |
| Büküm, N; Danielisová, P; Milan, J; Morell, A; Novotná, E; Wsól, V | 1 |
| Amadori, S; Appelbaum, FR; Bloomfield, CD; Brandwein, JM; Byrd, J; Chen, Y; Cheng, Y; de Witte, TM; Döhner, H; Döhner, K; Du, L; Ehninger, G; Ganser, A; Geyer, SM; Heuser, M; Jansen, JH; Jones, D; Krauter, J; Larson, RA; Lavorgna, S; Lo-Coco, F; Marcucci, G; Medeiros, BC; Niederwieser, D; Nomdedeu, J; Pallaud, C; Piciocchi, A; Prior, T; Sanz, MA; Schlenk, RF; Sierra, J; Stone, RM; Tallman, MS; Thiede, C; Voso, MT; Walker, A; Wei, AH | 1 |
| Beaver, L; Blachly, JS; Brinton, LT; Byrd, JC; Canfield, D; Cannon, M; Cempre, C; Govande, M; Harrington, B; Lapalombella, R; Lehman, A; Orwick, S; Sher, S; Skinner, J; Wasmuth, R; Williams, K; Zhang, P | 1 |
| Charlet, A; Döhner, K; Duyster, J; Endres, C; Fischer, T; Gorantla, SP; Haferlach, T; Heidel, FH; Meggendorfer, M; Rummelt, C; von Bubnoff, N | 1 |
| Fleischmann, M; Heidel, FH; Schnetzke, U; Scholl, S | 1 |
| Bonifacio, G; Deol, A; Fernandez, HF; Haines, K; Hernandez, D; Kim, DDH; Levis, M; Maziarz, RT; Mohan, SR; Patnaik, MM; Purkayastha, D; Rajkhowa, T; Rine, P; Rowley, SD; Scott, BL | 1 |
| Gu, XZ; Liu, JQ; Yu, LQ | 1 |
| Abuín Blanco, A; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Bendaña López, Á; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Melero Valentín, P; Montesinos Fernández, P; Mosquera Orgueira, A; Peleteiro Raíndo, A; Pérez Encinas, MM | 1 |
| Blätte, TJ; Bloomfield, CD; Bullinger, L; Cocciardi, S; Döhner, H; Döhner, K; Dolnik, A; Fiedler, W; Gaidzik, VI; Ganser, A; Herzig, J; Heuser, M; Jahn, N; Larson, RA; Lübbert, M; Minucci, S; Panina, E; Paschka, P; Rücker, FG; Salih, HR; Schlenk, RF; Schmalbrock, LK; Schroeder, T; Skambraks, S; Stone, RM; Sträng, E; Stunnenberg, HG; Theis, F; Thol, F; Wulf, G | 1 |
| Angelopoulou, MK; Chatzidimitriou, C; Konstantopoulos, K; Korkolopoulou, P; Lafioniatis, S; Lakiotaki, E; Pappa, V; Plata, E; Vassilakopoulos, TP | 1 |
| Amadori, S; Appelbaum, FR; Bloomfield, CD; Brandwein, JM; de Witte, T; Döhner, H; Döhner, K; Ehninger, G; Galinsky, I; Ganser, A; Gathmann, I; Geyer, S; Huebner, LJ; Klisovic, RB; Krauter, J; Larson, RA; Laumann, K; Mandrekar, SJ; Marcucci, G; Medeiros, BC; Niederwieser, D; Prior, TW; Sanford, BL; Sanz, MA; Schlenk, RF; Serve, H; Sierra, J; Stone, RM; Tallman, MS; Thiede, C; Voso, MT; Wei, AH | 1 |
| Del Principe, MI; Marchesi, F; Menna, P; Minotti, G; Pagano, L; Perrone, S; Salvatorelli, E | 1 |
| Bagnato, G; Cerchione, C; Giannini, MB; Marconi, G; Martinelli, G; Mosquera Orgueira, A; Musuraca, G; Simonetti, G | 1 |
| Amit, O; Avni, B; Bar-On, Y; Krayem, B; Pasvolsky, O; Peretz, G; Raanani, P; Ram, R; Rozovski, U; Shargian, L; Shimony, S; Wolach, O; Yeshurun, M; Zukerman, T | 1 |
| Arellano-Viera, E; Da Via, MC; Einsele, H; Eiring, P; Garitano-Trojaola, A; Gil-Pulido, J; Götz, R; Groll, J; Haertle, L; Hudecek, M; Jetani, H; Kortüm, MK; Kraus, S; Rasche, L; Rhodes, N; Rosenwald, A; Sancho, A; Sauer, M; Teufel, E; Tibes, R; Walz, S | 1 |
| Schuh, AC; Tang, K; Yee, KW | 1 |
| Alkassis, S; Chi, J; Daoud, L; Rizwan, A | 1 |
| Levis, M | 1 |
| Patnaik, MM | 2 |
| Kim, ES | 1 |
| Amadori, S; Appelbaum, FR; Bloomfield, CD; Brandwein, JM; de Witte, T; Döhner, H; Döhner, K; Ehninger, G; Ganser, A; Geyer, S; Klisovic, RB; Krauter, J; Larson, RA; Laumann, K; Lo-Coco, F; Mandrekar, SJ; Marcucci, G; Medeiros, BC; Niederwieser, D; Prior, TW; Sanford, BL; Sanz, MA; Schlenk, RF; Serve, H; Sierra, J; Stone, RM; Tallman, MS; Thiede, C; Wei, A | 1 |
| Das, M | 1 |
| Aschenbrenner, DS | 1 |
| Sheridan, C | 1 |
| Estey, E; Percival, ME | 1 |
| Kayser, S; Levis, MJ; Schlenk, RF | 1 |
| Pollyea, DA; Stansfield, LC | 1 |
| Tiong, IS; Wei, AH | 2 |
| DeAngelo, DJ; Luskin, MR | 1 |
| He, JJ; Liu, CY; Su, L; Sun, WL; Wang, YY; Zhang, W | 1 |
| Döhner, H; Larson, RA; Stone, RM | 1 |
| Eskazan, AE | 1 |
| Kumar, L; Sahoo, RK | 1 |
| Hughes, TP; Rasko, JEJ | 1 |
| Stone, RM | 1 |
| Kim, M; Williams, S | 1 |
| Stone, RM; Yogarajah, M | 1 |
| Garcia, JS; Percival, ME | 1 |
| Tollkuci, E | 1 |
| Chen, B; Zhou, F | 1 |
| Marques, MAT; Mueller, BU; Pabst, T; Seipel, K; Sidler, C | 1 |
| Le-Rademacher, JG; Mandrekar, SJ; Peterson, RA; Sanford, BL; Stone, RM; Therneau, TM | 1 |
| Cortes, JE; Rytting, ME; Short, NJ | 1 |
| Caravatti, G; Furet, P; Manley, PW; Roesel, J; Tran, P; Wagner, T; Wartmann, M | 1 |
| Besse, E; Brethon, B; Dufour, C; Dutreix, C; Fagioli, F; Ho, PA; Luciani, M; Pieters, R; Rizzari, C; Söderhäll, S; Stam, RW; Zwaan, CM | 1 |
| Sweet, K; Talati, C | 1 |
| Geswein, L; Mulseh, M; Seddon, A; Tollkuci, E | 1 |
| Campbell, P; Thomas, CM | 1 |
| Bhattacharyya, S; Bonifacio, G; Duchesneau, E; Guerin, A; Joseph, G; Li, N; Ndife, B; Stein, E; Vudumula, U; Xie, J | 1 |
| Alsharedi, M; Dotson, J; Elhamdani, A; Jamil, MO; Petryna, E | 1 |
| Akhtari, M; Alachkar, H; Gutierrez, L; Jang, M; Zhang, T | 1 |
| Mueller, BU; Pabst, T; Seipel, K | 1 |
| Gaspar, K; Sly, N | 1 |
| Altmann, H; Arndt, C; Bachmann, M; Bornhäuser, M; Fasslrinner, F; Feldmann, A; Koristka, S; Schmitz, M; von Bonin, M | 1 |
| Bixby, DL; Marini, BL; Perissinotti, AJ; Weis, TM | 1 |
| Raanani, P; Reiss Mintz, H; Shimony, S; Shoham, A; Shvartser Beryozkin, Y; Wolach, O | 1 |
| Brunner, AM | 1 |
| Dzinic, SH; Edwards, H; Ge, Y; Knight, T; Kushner, J; Lin, H; Ma, J; Polin, L; Qiao, X; Taub, JW; Wang, G; Wang, Y; White, K; Zhao, L; Zhao, S | 1 |
| Schlafer, D | 1 |
| Galinsky, I; Gray, N; Griffin, JD; Liu, F; Liu, Q; Mitsiades, C; Nelson, E; Nicolais, M; Nonami, A; Sattler, M; Smith, RW; Stone, R; Weisberg, E; Zhang, J; Zhang, X | 1 |
| Abhyankar, S; Aljitawi, O; Bhalla, KN; Dutreix, C; Fiskus, W; Fleming, A; Ganguly, S; Kambhampati, S; McGuirk, JP; Reyes, R; Wick, J; Williams, CB | 1 |
| Chi, HT; Hara, Y; Kano, Y; Ly, BT; Nakano, K; Sato, Y; Watanabe, T; Yamagishi, M | 1 |
| Lancet, JE | 1 |
| Abboud, CN; Cashen, A; Dipersio, JF; Fiala, M; McBride, A; Ramsingh, G; Stockerl-Goldstein, K; Uy, G; Vij, R; Westervelt, P | 1 |
| Andreeff, M; Cortes, J; Kantarjian, H; Pemmaraju, N; Ravandi, F | 1 |
| Andreeff, M; Borthakur, G; Cortes, J; Daver, N; Durand, M; Estrov, Z; Garcia-Manero, G; Kadia, T; Kantarjian, H; Konopleva, M; Levis, M; Nazha, A; Rajkhowa, T; Ravandi, F; Strati, P | 1 |
| Chi, HT; Dung, PC; Ly, BT; Sato, Y; Vu, HA; Xinh, PT | 1 |
| Cooper, BW; Craig, MD; Creger, RJ; Hamadani, M; Kindwall-Keller, TL; Lazarus, HM; Tse, WW | 1 |
| Antonakos, B; Barys, L; Cooke, VG; Cowens, K; Galinsky, I; Griffin, JD; Halilovic, E; Ito, M; Jeay, S; McDonough, SM; Nelson, E; Nonami, A; Ren, T; Sanda, T; Sattler, M; Simkin, I; Stone, R; Weisberg, E; Wiesmann, M; Wuerthner, JU; Yuan, J | 1 |
| Smith, LL | 1 |
| Sun, WL; Wang, YY | 1 |
| Bhatnagar, B; Blum, W; Canning, R; Devine, SM; Garzon, R; Geyer, S; Klisovic, R; Marcucci, G; Vasu, S; Walker, AR; Walsh, K; Wang, H; Wu, YZ | 1 |
| Dziadosz, M; Fischer, T; Lipka, DB; Wagner, MC | 1 |
| Cai, X; Ding, M; Sheng, Y; Shi, L; Weng, XQ; Wu, J | 1 |
| Bruserud, Ø; Nepstad, I; Tvedt, TH | 1 |
| Gatlik, E; Gu, H; He, H; Heimbach, T; Klein, K; Lin, W; Tedesco, V; Tran, P; Zhang, J | 1 |
| Barrett, R; Bold, G; Cools, J; Daley, JF; Fox, E; Furet, P; Galinsky, I; Gilliland, G; Griffin, JD; Hall-Meyers, E; Jiang, J; Kung, AL; Lazo-Kallanian, S; Moreno, D; Nelson, E; Ray, A; Roesel, J; Stone, R; Weisberg, E; Wright, RD | 1 |
| Eliasson, P; Jönsson, JI; Kraft, M; Labi, V; Lam, EW; Nordigården, A; Villunger, A | 1 |
| Böhmer, FD; Breitenbuecher, F; Carius, B; Fischer, T; Huber, C; Kasper, S; Kindler, T; Markova, B; Masson, K; Rönnstrand, L; Stauder, T | 1 |
| Böhmer, FD; Duyster, J; Fischer, T; Grundler, R; Heidel, F; Huber, C; Kancha, RK; Lipka, DB; Mahboobi, S; Mirea, FK; Naumann, M | 1 |
| Gore, SD | 1 |
| Tallman, M | 1 |
| Karp, J | 1 |
| Armstrong, RC; Belli, B; Bhagwat, SS; Brigham, D; Chao, Q; Cramer, MD; Gardner, MF; Gunawardane, RN; James, J; Karaman, MW; Levis, M; Pallares, G; Patel, HK; Pratz, KW; Sprankle, KG; Zarrinkar, PP | 1 |
| Cavelier, C; Demur, C; Didier, C; Ducommun, B; Manenti, S; Mansat-De Mas, V; Prade, N; Recher, C | 1 |
| Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A | 1 |
| Büchner, T; Krug, U; Lübbert, M | 1 |
| Freidlin, B; Korn, EL; McShane, LM | 1 |
| Ehninger, G; Koch, S; Mohr, B; Oelschlägel, U; Steudel, C; Stölzel, F; Thiede, C | 1 |
| Ahmad, R; Galinsky, I; Kharbanda, S; Kufe, D; Liu, S; Meyer, C; Nelson, E; Stone, R; Weisberg, E | 1 |
| Deangelo, DJ; Dutreix, C; Ehninger, G; Estey, E; Feldman, EJ; Fischer, T; Fox, E; Galinsky, I; Giles, FJ; Gilliland, DG; Huntsman-Labed, A; Klimek, VM; Lanza, C; Nimer, SD; Schiller, GJ; Stone, RM; Virkus, J | 1 |
| Cesano, A; Covey, T; Fantl, WJ; Huang, YW; Minden, MD; Nolan, GP; Putta, S; Rosen, DB | 1 |
| Burnett, A; Galkin, S; Knapper, S; Levis, M; Sato, T; Small, D; Smith, BD; White, P; Yang, X | 1 |
| Drabkin, HA; Gadgil, S; Hermanova, I; Kornblau, SM; Qiu, YH; Starkova, J; Zhang, N | 1 |
| Chabner, BA; Fathi, AT | 1 |
| Adamia, S; Barrett, R; Daley, JF; Fox, E; Frank, D; Griffin, JD; Nelson, E; Ray, A; Sattler, M; Weisberg, E; Zhang, C | 1 |
| Bronson, R; Christie, AL; Daley, JF; Galinsky, I; Gray, N; Griffin, JD; Hur, W; Kung, AL; Liu, Q; Mitsiades, C; Nelson, E; Sanda, T; Sattler, M; Smith, R; Stone, R; Weisberg, E; Zhao, Z | 1 |
| Cortes, J; Daver, N | 1 |
| Freeman, C; Giles, F; Swords, R | 1 |
| Cortes, J; DeAngelo, DJ; del Corral, A; Dutreix, C; Ehninger, G; Fischer, T; Giles, F; Huntsman-Labed, A; Kantarjian, HM; Paquette, R; Schiffer, CA; Schiller, G; Stone, RM | 1 |
| Bhatt, L; Chang, CJ; Cotter, TG; Dickinson, BC; Gough, DR; Naughton, R; Stanicka, J; Woolley, JF | 1 |
| Böhmer, FD; Bolck, HA; Buchwald, M; Bug, G; Heinzel, T; Krämer, OH; Pietschmann, K; Polzer, H; Spiekermann, K; Spielberg, S | 1 |
| Albers, C; Duyster, J; Illert, AL; Leischner, H; Peschel, C; Verbeek, M; von Bubnoff, N; Yu, C | 1 |
| Boulton, C; Fabbro, D; Gilliland, DG; Griffin, JD; Kelly, LM; Manley, P; Meyer, T; Weisberg, E | 1 |
| Annavarapu, S; Bali, P; Bhalla, K; Cohen, P; Fiskus, W; George, P; Guo, F; Moscinski, L; Scuto, A; Sigua, C; Tao, J; Vishvanath, A | 1 |
| Bo, R; Boggon, TJ; DeAngelo, DJ; Eck, MJ; Fox, EA; Galinsky, I; Gilliland, DG; Griffin, JD; Herman, P; Jiang, J; Jonasova, A; Lee, JC; Meyerson, M; Paez, JG; Sellers, WR; Stone, RM; Weisberg, E; Wolpin, BM | 1 |
| Annavarapu, S; Atadja, P; Bali, P; Bhalla, K; Cohen, P; Fiskus, W; George, P; Guo, F; Moscinski, L; Scuto, A; Sigua, C; Tao, J; Vishvanath, A | 1 |
| Clark, J; Cohen, P; DeAngelo, DJ; Estey, E; Fox, EA; Galinsky, I; Gilliland, DG; Grandin, W; Griffin, JD; Klimek, V; Lebwohl, D; Neuberg, D; Nimer, SD; Stone, RM; Wang, Y | 1 |
| Zhang, GS | 1 |
| Azuma, A; Chubb, S; Guo, Y; Hittelman, W; Huang, P; Jiang, Y; Li, Y; Liu, X; Matsuda, A; Plunkett, W | 1 |
| Andreeff, M; Cortes, J; Du, M; Estrov, Z; Gandhi, V; Plunkett, W; Sampath, D; Shi, Z | 1 |
| Bagrintseva, K; Ellwart, JW; Hiddemann, W; Hopfner, KP; Reindl, C; Schnittger, S; Spiekermann, K; Vempati, S; Wenig, K | 1 |
| Berdel, WE; Müller-Tidow, C; Serve, H; Tickenbrock, L | 1 |
| Carter, GI; Grundy, M; Hunter, HM; Lloyd-Lewis, B; Massip, AM; Pallis, M; Russell, NH; Seedhouse, CH; Shang, S | 1 |
| Guo, L; Liu, X; Nishikawa, K; Plunkett, W | 1 |
| Duyster, J; Grundler, R; Kancha, RK; Peschel, C | 1 |
| Andersson, A; Bengtzen, S; Deneberg, S; Fioretos, T; Jonsson-Videsäter, K; Lehmann, S; Möllgård, L; Nahi, H; Paul, C | 1 |
| Furukawa, Y; Futaki, K; Kano, Y; Kikuchi, J; Odgerel, T; Shimizu, R; Wada, T | 1 |
| Cavelier, C; Demur, C; Didier, C; Ducommun, B; Galcera, MO; Laurent, G; Manenti, S; Quaranta, M | 1 |
| Ehninger, G; Illmer, T | 1 |
| Gary Gilliland, D; Tam, WF | 1 |
| Cáceres-Cortés, J; Dumouchel, J; Haddad, P; Hoang, T; Rajotte, D | 1 |
| Hattori, M; Honma, Y; Hozumi, M; Makishima, M; Motoyoshi, K; Nagata, N; Sampi, K | 1 |
| Bailly, JD; Cassar, G; Demur, C; Huynh, A; Jaffrézou, JP; Laredo, J; Laurent, G; Muller, C | 1 |
| Pommier, Y; Shao, RG; Shimizu, T | 1 |
| Hagino, T; Kobayashi, D; Niitsu, Y; Okamoto, T; Sasaki, H; Sato, T; Tsuji, N; Watanabe, N; Yamauchi, N | 1 |
| Azuma, A; Huang, P; Li, YX; Plunkett, W; Sampath, D; Shi, Z | 1 |
54 review(s) available for staurosporine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML.
Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine | 2023 |
Midostaurin for patients with acute myeloid leukemia and FLT3 mutations.
Topics: fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine | 2019 |
[What is recommended in the treatment of acute myeloid leukemia?]
Topics: Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Germany; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Quality of Life; Staurosporine; Sulfonamides | 2019 |
Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
Topics: Allografts; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Staurosporine | 2019 |
Will new agents impact survival in AML?
Topics: Aniline Compounds; Disease-Free Survival; Drug Approval; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pyrazines; Staurosporine; Survival Rate; United States | 2019 |
The growing landscape of FLT3 inhibition in AML.
Topics: Allografts; Aniline Compounds; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Middle Aged; Pyrazines; Staurosporine; Stem Cell Transplantation | 2019 |
Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
Topics: Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Drug Approval; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Staurosporine; Sulfonamides; United States; United States Food and Drug Administration | 2020 |
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; DNA Methylation; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Piperidines; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2020 |
Overcoming Resistance to FLT3 Inhibitors in the Treatment of
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Drug Therapy, Combination; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Staurosporine | 2020 |
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Pyridines; Recurrence; Remission Induction; Staurosporine; Sulfonamides | 2020 |
European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Edema; European Union; Fatigue; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Nausea; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Staurosporine; Vomiting | 2019 |
Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma.
Topics: Antifungal Agents; Chemoprevention; Drug Interactions; Drugs, Investigational; Humans; Invasive Fungal Infections; Leukemia, Myeloid, Acute; Prognosis; Staurosporine; Triazoles | 2020 |
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines | 2020 |
Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.
Topics: Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytochrome P-450 CYP3A Inhibitors; Drug Approval; Drug Interactions; Drugs, Investigational; Humans; Leukemia, Myeloid, Acute; Long QT Syndrome; Phenylurea Compounds; Protein Kinase Inhibitors; Staurosporine; Sulfonamides | 2020 |
Acute myeloid leukemia: 2021 update on risk-stratification and management.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Gemtuzumab; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Risk Assessment; Staurosporine; Sulfonamides; United States | 2020 |
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Forecasting; Furans; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Phenylurea Compounds; Piperidines; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Pyridazines; Recurrence; Sorafenib; Staurosporine | 2020 |
Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
Topics: Aniline Compounds; Anthracyclines; Antifungal Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Echinocandins; fms-Like Tyrosine Kinase 3; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Mycoses; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Staurosporine; Triazoles | 2020 |
Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.
Topics: Aniline Compounds; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Pyrazines; Staurosporine | 2020 |
The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzothiazoles; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Staurosporine | 2021 |
3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Risk Assessment; Staurosporine | 2021 |
Midostaurin approved for FLT3-mutated AML.
Topics: Antineoplastic Agents; Drug Approval; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine | 2017 |
Midostaurin for the treatment of acute myeloid leukemia.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Prognosis; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2017 |
Midostaurin: First Global Approval.
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Approval; Humans; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Middle Aged; Protein Kinase Inhibitors; Staurosporine; United States; United States Food and Drug Administration; Young Adult | 2017 |
Emerging treatments in acute myeloid leukemia: current standards and unmet challenges.
Topics: Allografts; Consolidation Chemotherapy; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm, Residual; Staurosporine | 2017 |
Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Topics: Adult; Animals; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Mutation; Protein Kinase Inhibitors; Staurosporine | 2017 |
Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
Topics: Administration, Oral; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine | 2017 |
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Liposomes; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins c-bcl-2; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Treatment Outcome; Triazines | 2017 |
Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Drug Approval; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2017 |
Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine | 2017 |
The importance of FLT3 mutational analysis in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gain of Function Mutation; Genetic Testing; Humans; Leukemia, Myeloid, Acute; Prognosis; Protein Domains; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2018 |
Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2018 |
A concise review of BCL-2 inhibition in acute myeloid leukemia.
Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2; Staurosporine; Triazines | 2018 |
Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Drug Interactions; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Staurosporine | 2017 |
Acute myeloid leukemia carrying ETV6 mutations: biologic and clinical features.
Topics: Benzamides; ETS Translocation Variant 6 Protein; Gene Rearrangement; Humans; Indazoles; Leukemia, Myeloid, Acute; Mutation; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-ets; Repressor Proteins; Staurosporine; Tumor Microenvironment | 2018 |
Acute myeloid leukaemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Gemtuzumab; Genomics; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Patient Selection; Recurrence; Remission Induction; Risk Assessment; Risk Factors; Staurosporine | 2018 |
Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Cytarabine; Daunorubicin; Female; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Pyridines; Staurosporine; Triazines | 2018 |
FLT3 inhibitors in acute myeloid leukemia: Current and future.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Forecasting; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine | 2019 |
Myelodysplastic syndromes and acute myeloid leukemias in the elderly.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Gemtuzumab; Geriatric Assessment; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Staurosporine | 2018 |
Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis.
Topics: Antineoplastic Agents; Disease Management; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Mutation; Staurosporine | 2019 |
New drugs creating new challenges in acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Pyrazines; Pyridines; Staurosporine; Triazines; United States; United States Food and Drug Administration | 2019 |
Availability of FLT3 inhibitors: how do we use them?
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzothiazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Staurosporine | 2019 |
Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Staurosporine | 2019 |
Management of Midostaurin-CYP3A4 Drug-Drug Interactions in Patients With Acute Myeloid Leukemia.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Staurosporine | 2019 |
New agents: great expectations not realized.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Benzothiazoles; Cytosine; Gemtuzumab; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Naphthyridines; Phenylurea Compounds; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Staurosporine; Survival Analysis; Thiazoles; Treatment Failure; Vorinostat | 2013 |
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridazines; Sorafenib; Staurosporine | 2014 |
[Research Progress on Treating Acute Myeloid Leukemia by Midostaurin].
Topics: Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine | 2015 |
Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.
Topics: Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Staurosporine; Stromal Cells; Survival Rate | 2017 |
Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?
Topics: Azacitidine; Benzenesulfonates; Decitabine; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Prenylation; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Staurosporine | 2010 |
Molecular targeted therapy in acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; fms-Like Tyrosine Kinase 3; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; ras Proteins; Sorafenib; Staurosporine | 2012 |
Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.
Topics: Benzenesulfonates; Benzothiazoles; Carbazoles; CCAAT-Enhancer-Binding Protein-alpha; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Staurosporine | 2012 |
Emerging Flt3 kinase inhibitors in the treatment of leukaemia.
Topics: Animals; Antineoplastic Agents; Carbazoles; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Staurosporine | 2006 |
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib | 2007 |
Can FLT3 inhibitors overcome resistance in AML?
Topics: Antineoplastic Agents; Carbazoles; Clinical Trials as Topic; Drug Design; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Piperazines; Quinazolines; Staurosporine | 2008 |
19 trial(s) available for staurosporine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
Topics: Adolescent; Adult; Aged; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Protein-Tyrosine Kinases; Staurosporine; Young Adult | 2022 |
Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine | 2022 |
Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial.
Topics: Aged; Anthracyclines; Antibiotics, Antineoplastic; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Staurosporine | 2023 |
Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study.
Topics: Adult; Aged; Aged, 80 and over; Critical Care; Daunorubicin; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Staurosporine; Survival Rate | 2019 |
A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Staurosporine | 2020 |
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Staurosporine; Stem Cell Transplantation; Young Adult | 2021 |
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
Topics: Adolescent; Adult; Aged; Clonal Evolution; Exome Sequencing; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Staurosporine; Tandem Repeat Sequences | 2021 |
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
Topics: Adolescent; Adult; Antineoplastic Agents; Biomarkers, Tumor; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Staurosporine; Survival Rate; Young Adult | 2021 |
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Staurosporine; Young Adult | 2017 |
A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia.
Topics: Adolescent; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Staurosporine; Survival Rate | 2019 |
Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cytarabine; Daunorubicin; Double-Blind Method; Female; fms-Like Tyrosine Kinase 3; Health Care Costs; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Theoretical; Quality-Adjusted Life Years; Staurosporine; Survival Rate; Treatment Outcome; United States | 2019 |
Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cohort Studies; Decitabine; Drug Synergism; Female; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Recurrence; Staurosporine | 2013 |
Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Recurrence; Remission Induction; Staurosporine; Treatment Outcome; Tretinoin | 2014 |
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Staurosporine; Young Adult | 2015 |
A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Staurosporine; Treatment Outcome | 2015 |
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Myelodysplastic Syndromes; Receptor Protein-Tyrosine Kinases; Staurosporine; Treatment Outcome | 2010 |
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Remission Induction; Staurosporine; Survival Rate; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
Topics: Adult; Aged; Blood Cell Count; Bone Marrow; Enzyme Activation; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Phosphotyrosine; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Staurosporine | 2005 |
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blast Crisis; Cell Cycle; Checkpoint Kinase 1; Cyclin-Dependent Kinase 2; Cytarabine; DNA Damage; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid, Acute; Middle Aged; Oncogene Protein v-akt; Pharmacokinetics; Phosphorylation; Pilot Projects; Protein Kinases; Salvage Therapy; Staurosporine; Tumor Cells, Cultured | 2006 |
114 other study(ies) available for staurosporine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Aurora Kinase B; Cell Line, Tumor; Chlorocebus aethiops; Drug Design; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Mice; Protein Kinase Inhibitors; Vero Cells; Xenograft Model Antitumor Assays | 2014 |
Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Mutation; Phosphorylation; Protein Kinase Inhibitors; Pteridines | 2016 |
Bullous Sweet syndrome in a patient with acute myeloid leukemia treated with midostaurin: Rapid response to acitretin and colchicine-A case report.
Topics: Acitretin; Colchicine; Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine; Sweet Syndrome | 2021 |
FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells.
Topics: Benzothiazoles; Cell Membrane; Cell Proliferation; Endoplasmic Reticulum; Extracellular Signal-Regulated MAP Kinases; fms-Like Tyrosine Kinase 3; Golgi Apparatus; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mutation; Oncogenes; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; STAT5 Transcription Factor; Staurosporine; Tandem Repeat Sequences; THP-1 Cells; Tumor Suppressor Proteins | 2021 |
Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin.
Topics: Antifungal Agents; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine | 2022 |
ABCB1 as a potential beneficial target of midostaurin in acute myeloid leukemia.
Topics: Anthracyclines; ATP Binding Cassette Transporter, Subfamily B; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; MicroRNAs; Mutation; Protein Kinase Inhibitors; Staurosporine | 2022 |
The FLT3 Y842D mutation may be highly sensitive to midostaurin: a case report.
Topics: fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine | 2022 |
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Retrospective Studies; Sorafenib; Staurosporine | 2022 |
Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3.
Topics: Animals; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Staurosporine; Tretinoin | 2022 |
Midostaurin as the Most Likely Cause of Bilateral Adrenal Masses in a Patient with Acute Myeloid Leukemia.
Topics: Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine | 2022 |
Feasibility of autologous peripheral blood stem cell mobilization and harvest in adult patients with FLT3-mutated acute myeloid leukemia receiving chemotherapy combined with midostaurin: a single-center experience.
Topics: Adult; Feasibility Studies; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Peripheral Blood Stem Cells; Protein Kinase Inhibitors; Staurosporine | 2023 |
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.
Topics: Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine | 2023 |
Real-World Efficacy Outcomes of FLT3-ITD
Topics: fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine | 2023 |
Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for
Topics: Czech Republic; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Staurosporine | 2023 |
Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mutation; Remission Induction; Staurosporine | 2023 |
Improving Response to FLT3 Inhibitors-BCL2 the Rescue?
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Staurosporine | 2019 |
Real-Time NMR Spectroscopy for Studying Metabolism.
Topics: Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Glucose; Humans; Lactic Acid; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Magnetic Resonance Spectroscopy; Metabolome; Metabolomics; Staurosporine | 2020 |
Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis.
Topics: Antineoplastic Agents; Humans; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Nausea; Staurosporine; United States; Vomiting | 2019 |
Treatment practice and outcomes in
Topics: Australia; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine; Tertiary Care Centers | 2020 |
Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.
Topics: Adult; Aged; Cohort Studies; Comprehensive Health Care; Female; fms-Like Tyrosine Kinase 3; Health Care Costs; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Staurosporine; Treatment Outcome | 2019 |
How I treat acute myeloid leukemia in the era of new drugs.
Topics: Adult; Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Mutation; Prognosis; Pyrazines; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Triazines | 2020 |
MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia.
Topics: Adult; Aged; Animals; Antigens, CD34; Bone Marrow Cells; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; MAP Kinase Kinase Kinase 1; MAP Kinase Signaling System; Mice; Middle Aged; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Staurosporine | 2019 |
Monocytic Maturation Induced by FLT3 Inhibitor Therapy of Acute Myeloid Leukemia: Morphologic and Immunophenotypic Characteristics.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cell Differentiation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Monocytes; Staurosporine; Young Adult | 2020 |
Pregnancy exposure to midostaurin in the first trimester.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Compassionate Use Trials; Cytarabine; Female; Fetal Growth Retardation; fms-Like Tyrosine Kinase 3; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Leukemia, Myeloid, Acute; Mutation; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Protein Kinase Inhibitors; Recurrence; Staurosporine; Tandem Repeat Sequences | 2020 |
Unique case of ANCA-negative pauci-immune necrotizing glomerulonephritis with diffuse alveolar hemorrhage, potentially associated with midostaurin.
Topics: Acute Kidney Injury; Administration, Intravenous; Antibodies, Antineutrophil Cytoplasmic; Biopsy; Combined Modality Therapy; Cyclophosphamide; Glomerulonephritis; Glucocorticoids; Hemorrhage; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lung Diseases; Methylprednisolone; Middle Aged; Necrosis; Plasma Exchange; Protein Kinase Inhibitors; Renal Dialysis; Staurosporine; Treatment Outcome | 2020 |
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.
Topics: Cell Line, Tumor; Chemokine CCL5; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine; Up-Regulation | 2020 |
Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Staurosporine; Syk Kinase | 2020 |
Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; fms-Like Tyrosine Kinase 3; France; Health Expenditures; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Models, Econometric; Quality-Adjusted Life Years; Recurrence; Remission Induction; Staurosporine | 2020 |
The successful use of
Topics: fms-Like Tyrosine Kinase 3; Humans; Leukemia; Leukemia, Myeloid, Acute; Phenotype; Protein Kinase Inhibitors; Staurosporine | 2020 |
Updated safety of midostaurin plus chemotherapy in newly diagnosed
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Radius; Staurosporine | 2020 |
Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Gene Frequency; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Staurosporine; Transplantation, Homologous; Treatment Outcome | 2021 |
Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism.
Topics: Aldo-Keto Reductase Family 1 Member C3; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Colorectal Neoplasms; Daunorubicin; Drug Synergism; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; HCT116 Cells; Humans; Leukemia, Myeloid, Acute; Staurosporine | 2021 |
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.
Topics: fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Nucleophosmin; Staurosporine | 2020 |
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; CRISPR-Cas Systems; Female; fms-Like Tyrosine Kinase 3; Gene Knockout Techniques; Genetic Therapy; Humans; Leukemia, Myeloid, Acute; Mice, SCID; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Staurosporine; Sulfonamides | 2020 |
Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Janus Kinases; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Sorafenib; Staurosporine; Tandem Repeat Sequences | 2021 |
[Inhibitory Effect of PKC412 Against Human Acute Leukemia Cell Line HL-60 Cells].
Topics: Animals; Apoptosis; Cell Proliferation; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Proto-Oncogene Proteins c-bcl-2; Staurosporine | 2021 |
Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.
Topics: Biomarkers; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Humans; Leukemia; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins; Nucleophosmin; Staurosporine | 2021 |
Pancytopenia, eosinophilia and coagulation disorders in a patient with T-acute lymphoblastic leukemia in prolonged remission.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Blood Cell Count; Bone Marrow; Cancer Survivors; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 7; Diagnosis, Differential; Eosinophilia; Hemorrhagic Disorders; Humans; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pancytopenia; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Staurosporine; Tryptases | 2021 |
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life.
Topics: Adult; Aged; Antifungal Agents; Antineoplastic Agents; Cytochrome P-450 CYP3A; Diarrhea; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Mycoses; Staurosporine; Triazoles | 2021 |
Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients - a multicenter retrospective observational study.
Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Sorafenib; Staurosporine | 2021 |
Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia.
Topics: Actin Cytoskeleton; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Proto-Oncogene Proteins c-bcl-2; Pyrones; Quinolines; rac1 GTP-Binding Protein; Staurosporine; Sulfonamides | 2021 |
Midostaurin-induced Sweet syndrome in a patient with FLT3-ITD-positive AML.
Topics: fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Staurosporine; Sweet Syndrome; United States | 2021 |
Midostaurin Gets FDA Nod for AML.
Topics: Drug Approval; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib; Staurosporine; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Midostaurin in FLT3-mutated acute myeloid leukaemia.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Staurosporine; Treatment Outcome | 2017 |
New Approvals in Cancer Treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Approval; Humans; Leukemia, Myeloid, Acute; Liver Neoplasms; Phenylurea Compounds; Pyridines; Staurosporine; United States; United States Food and Drug Administration | 2017 |
First new drug approval for AML in 15 years.
Topics: Aminoglycosides; Aminopyridines; Aniline Compounds; Antibodies, Monoclonal, Humanized; Drug Approval; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Staurosporine; Triazines | 2017 |
[Sensitivity of AML Cells with FLT3
Topics: Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine | 2017 |
Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
Topics: Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine | 2017 |
Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
Topics: Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine | 2017 |
Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
Topics: Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine | 2017 |
First Approved Kinase Inhibitor for AML.
Topics: Antineoplastic Agents; Drug Approval; Humans; Leukemia, Myeloid, Acute; Staurosporine; United States; United States Food and Drug Administration | 2017 |
Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.
Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Nitriles; Protein Kinase Inhibitors; Pyridines; Staurosporine; Triazoles | 2019 |
MDM2- and FLT3-inhibitors in the treatment of
Topics: Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitors; Female; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Nucleophosmin; Proto-Oncogene Proteins c-mdm2; Staurosporine | 2018 |
Application of multi-state models in cancer clinical trials.
Topics: Antineoplastic Agents; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Models, Statistical; Proportional Hazards Models; Randomized Controlled Trials as Topic; Remission Induction; Statistics, Nonparametric; Staurosporine; Survival Analysis | 2018 |
Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy.
Topics: Animals; BALB 3T3 Cells; Cell Proliferation; Cells, Cultured; Fibroblasts; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Protein Kinase Inhibitors; Staurosporine | 2018 |
Midostaurin administration in two hemodialysis patients.
Topics: Aged; Antineoplastic Agents; Female; Humans; Kidney Failure, Chronic; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Kinase Inhibitors; Renal Dialysis; Staurosporine | 2019 |
Neutropenic enterocolitis in patients with FLT3 mutated acute myeloid leukemia undergoing induction chemotherapy with midostaurin.
Topics: Adult; Aged; Enterocolitis, Neutropenic; Female; fms-Like Tyrosine Kinase 3; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Staurosporine | 2019 |
Midostaurin reduces Regulatory T cells markers in Acute Myeloid Leukemia.
Topics: Antigens, Differentiation; Cytokines; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Signal Transduction; Staurosporine; T-Lymphocytes, Regulatory | 2018 |
Closing in on targeted therapy for acute myeloid leukaemia.
Topics: Aniline Compounds; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Pyrazines; Staurosporine | 2019 |
Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia.
Topics: Antineoplastic Agents; Humans; Leukemia, Myeloid, Acute; Sialic Acid Binding Ig-like Lectin 3; Staurosporine | 2019 |
Necrotizing Hemorrhagic Gastritis following Acute Myeloid Leukemia Induction with Midostaurin: An Unexpected Complication.
Topics: Abdominal Pain; Gastritis; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Kinase Inhibitors; Remission Induction; Staurosporine; Tomography, X-Ray Computed | 2020 |
Acute Myeloid Leukemia: A New Era of Therapies, a New Wave of Toxicities?
Topics: Acute Disease; Gastritis; Humans; Leukemia, Myeloid, Acute; Staurosporine | 2020 |
Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Topics: Aniline Compounds; Animals; Apoptosis; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; fms-Like Tyrosine Kinase 3; Gene Duplication; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Staurosporine; Sulfonamides; Xenograft Model Antitumor Assays | 2019 |
Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.
Topics: Apoptosis; Benzothiazoles; Bone Marrow Cells; Cell Communication; Cell Cycle; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Staurosporine; Stromal Cells | 2013 |
Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cells.
Topics: Antineoplastic Agents; Catechin; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression; Gene Expression Regulation, Leukemic; HSP90 Heat-Shock Proteins; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mitogen-Activated Protein Kinases; Mutagenesis, Insertional; Phosphorylation; Point Mutation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; STAT5 Transcription Factor; Staurosporine | 2013 |
Synergistic effect of all‑trans retinoic acid in combination with protein kinase C 412 in FMS-like tyrosine kinase 3-mutated acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine; Tretinoin | 2015 |
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Gene Expression; Humans; Inhibitory Concentration 50; Isoquinolines; Leukemia, Myeloid, Acute; Mice, Inbred NOD; Mice, SCID; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-mdm2; Staurosporine; Tumor Burden; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
57th American Society of Hematology Annual Meeting.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Aurora Kinase A; Azepines; Chimera; fms-Like Tyrosine Kinase 3; Fusion Proteins, bcr-abl; Hematology; Humans; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Peripheral; Multiple Myeloma; Pyrimidines; Societies, Medical; Staurosporine; T-Lymphocytes; United States | 2016 |
Midostaurin + Chemo Ups AML Survival.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Congresses as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Staurosporine; Survival Analysis; Treatment Outcome | 2016 |
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Cytarabine; Drug Monitoring; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retreatment; Staurosporine; Treatment Outcome; Young Adult | 2016 |
Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias.
Topics: Animals; Antineoplastic Agents; Culture Media; Dose-Response Relationship, Drug; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Staurosporine | 2016 |
Staurosporine enhances ATRA-induced granulocytic differentiation in human leukemia U937 cells via the MEK/ERK signaling pathway.
Topics: CCAAT-Enhancer-Binding Protein-beta; Cell Differentiation; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Staurosporine; Tretinoin; U937 Cells | 2016 |
Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug.
Topics: Adult; Animals; Dogs; Female; Humans; Leukemia, Myeloid, Acute; Male; Mass Spectrometry; Middle Aged; Protein Kinase Inhibitors; Rats; Staurosporine; Young Adult | 2017 |
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbanilides; Cell Line; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Leukemia, Myeloid, Acute; Mice; Mutant Proteins; Protein Kinase C; Protein Kinase Inhibitors; Staurosporine | 2008 |
BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Forkhead Box Protein O3; Forkhead Transcription Factors; Hematopoietic Stem Cells; Humans; Immunoprecipitation; Leukemia, Myeloid, Acute; Membrane Proteins; Mice; Mutation; Oligonucleotide Array Sequence Analysis; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Signal Transduction; Staurosporine; Transduction, Genetic; Tyrphostins | 2009 |
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phenotype; Protein Array Analysis; Signal Transduction; Staurosporine; Substrate Specificity; Up-Regulation | 2009 |
Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Line; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Staurosporine; Tandem Repeat Sequences; Transfection; Tumor Cells, Cultured | 2009 |
New agents for the treatment of AML recent study findings.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Carbazoles; Clofarabine; Decitabine; Enzyme Inhibitors; Furans; Humans; Hydrazines; Immunotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Quinolones; Staurosporine; Sulfonamides; Thalidomide | 2008 |
Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Topics: Adenine; Adenine Nucleotides; Aminoglycosides; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Carbazoles; Clofarabine; Cytarabine; Dasatinib; Daunorubicin; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Naphthalimides; Organophosphonates; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sesquiterpenes; Staurosporine; Stem Cell Transplantation; Thiazoles; Tretinoin | 2008 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Topics: Animals; Benzenesulfonates; Benzothiazoles; Bone Marrow; Carbazoles; Cell Line, Tumor; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Prognosis; Protein Interaction Mapping; Protein Kinase C; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Staurosporine; Xenograft Model Antitumor Assays | 2009 |
Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Checkpoint Kinase 1; Child; Chromosome Aberrations; DNA Damage; Flow Cytometry; Fluorescent Antibody Technique; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Middle Aged; Protein Kinases; RNA Interference; Signal Transduction; Staurosporine | 2009 |
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2010 |
Randomized clinical trials with biomarkers: design issues.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; DNA-Binding Proteins; Endonucleases; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Staurosporine | 2010 |
Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
Topics: Cell Line, Tumor; Chromosomes, Human, Pair 13; Clinical Trials as Topic; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Mutation; Oligonucleotide Array Sequence Analysis; Prognosis; Protein Kinase Inhibitors; Staurosporine | 2010 |
Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation.
Topics: Aged; Aged, 80 and over; Animals; Apoptosis; Caspase 3; Cell Growth Processes; Cell Survival; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mutation; Oleanolic Acid; Phosphorylation; Signal Transduction; Staurosporine | 2010 |
Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemia.
Topics: Apoptosis; DNA Damage; Etoposide; Humans; Intracellular Space; Janus Kinases; Leukemia, Myeloid, Acute; Phosphatidylinositol 3-Kinases; Signal Transduction; STAT Transcription Factors; Staurosporine | 2010 |
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
Topics: Antineoplastic Agents; Benzenesulfonates; Carbazoles; Cells, Cultured; Drug Antagonism; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Membrane Proteins; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2011 |
Up-regulation of homeodomain genes, DLX1 and DLX2, by FLT3 signaling.
Topics: Antigens, Surface; Cell Line, Tumor; Cell Nucleus; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Gene Silencing; Homeodomain Proteins; Humans; Leukemia, Myeloid, Acute; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Smad2 Protein; Staurosporine; Transcription Factors; Transforming Growth Factor beta; Up-Regulation | 2011 |
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
Topics: Antineoplastic Agents; Benzothiazoles; Carbazoles; Clinical Trials as Topic; Cytokines; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyrroles; Staurosporine; Sunitinib; Tandem Repeat Sequences | 2011 |
Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Stability; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Half-Life; Humans; Leukemia, Myeloid, Acute; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; RNA, Messenger; Signal Transduction; Staurosporine; Thiazoles; Tyrosine; Up-Regulation | 2011 |
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Janus Kinases; Leukemia, Myeloid, Acute; Mice; Mutation; Protein Kinase Inhibitors; Pyrimidines; STAT5 Transcription Factor; Staurosporine; Stromal Cells; Thiazoles | 2012 |
H2O2 production downstream of FLT3 is mediated by p22phox in the endoplasmic reticulum and is required for STAT5 signalling.
Topics: Benzoxazoles; Cell Line, Tumor; Endoplasmic Reticulum; Fluorescent Dyes; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Hydrogen Peroxide; Imidazoles; Leukemia, Myeloid, Acute; Mitochondria; Mutation; NADPH Oxidases; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-pim-1; Pyrroles; RNA, Small Interfering; Signal Transduction; STAT5 Transcription Factor; Staurosporine; Triazoles | 2012 |
Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
Topics: Apoptosis; Benzothiazoles; Caspases; Cell Line; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Duplication; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; Panobinostat; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Stability; Proteolysis; Signal Transduction; STAT5 Transcription Factor; Staurosporine | 2012 |
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.
Topics: Antineoplastic Agents; Benzothiazoles; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Phenylurea Compounds; Pyrroles; Staurosporine; Sunitinib | 2013 |
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone Marrow Cells; Bone Marrow Transplantation; Cell Cycle; Cell Division; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Imatinib Mesylate; Immunoblotting; Interleukin-3; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Phosphorylation; Piperazines; Protein Kinase C; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; Staurosporine; Transfection; Tumor Cells, Cultured | 2002 |
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Cysteine Endopeptidases; DNA-Binding Proteins; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; G1 Phase; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukemia, Myeloid, Acute; Milk Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Multienzyme Complexes; Proteasome Endopeptidase Complex; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Rifabutin; Signal Transduction; STAT5 Transcription Factor; Staurosporine; Trans-Activators; Ubiquitin | 2004 |
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.
Topics: Adult; Aged; Aged, 80 and over; Cell Division; Enzyme Activation; Female; fms-Like Tyrosine Kinase 3; Humans; Hydrogen Bonding; Interleukin-3; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Molecular; Mutation; Phosphorylation; Protein Structure, Tertiary; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Signal Transduction; Staurosporine | 2004 |
Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; DNA; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Enzyme Inhibitors; Exons; Flow Cytometry; fms-Like Tyrosine Kinase 3; G1 Phase; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Milk Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Phosphorylation; Proteasome Endopeptidase Complex; Protein Binding; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; STAT5 Transcription Factor; Staurosporine; Time Factors; Trans-Activators | 2004 |
[New targets for molecular therapy of acute leukemia: a "single-hit" or "multiple-hit" strategy against signaling pathway].
Topics: Acute Disease; Antineoplastic Agents; Carbazoles; Furans; Humans; Indoles; Leukemia; Leukemia, Myeloid, Acute; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Quinolones; ras Proteins; Staurosporine | 2005 |
Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
Topics: Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Checkpoint Kinase 1; Chromosome Aberrations; Cytarabine; DNA Damage; Drug Interactions; G2 Phase; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Mitosis; Protein Kinases; Signal Transduction; Staurosporine | 2005 |
Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.
Topics: Amino Acid Sequence; Animals; Apoptosis; Base Sequence; Cell Line; DNA, Neoplasm; Enzyme Activation; fms-Like Tyrosine Kinase 3; Humans; In Vitro Techniques; Interleukin-3; Leukemia, Myeloid, Acute; Mice; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Phosphorylation; Point Mutation; Protein Structure, Tertiary; Recombinant Proteins; STAT5 Transcription Factor; Staurosporine; Tyrosine | 2006 |
DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
Topics: DNA Repair; Drug Resistance, Neoplasm; Etoposide; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Phenotype; Phosphorylation; Protein Kinase Inhibitors; Rad51 Recombinase; RNA, Small Interfering; STAT5 Transcription Factor; Staurosporine; Tandem Repeat Sequences | 2006 |
Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Chromosome Aberrations; Clinical Trials as Topic; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; G2 Phase; Histones; Humans; Leukemia, Myeloid, Acute; Phenanthrenes; Phenanthridines; Phosphorylation; Staurosporine; Topoisomerase II Inhibitors | 2007 |
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2007 |
The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Staurosporine | 2008 |
The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations.
Topics: Apoptosis; bcl-Associated Death Protein; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin B; Cyclin-Dependent Kinases; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Phosphorylation; Serine; Signal Transduction; Staurosporine; U937 Cells | 2008 |
G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress.
Topics: Antigens, CD; Antigens, CD34; Antineoplastic Agents; cdc25 Phosphatases; Cell Division; Cell Line, Tumor; Colony-Forming Units Assay; G2 Phase; Humans; Leukemia, Myeloid, Acute; Mitosis; Nocodazole; Staurosporine; U937 Cells | 2008 |
Product of the steel locus suppresses apoptosis in hemopoietic cells. Comparison with pathways activated by granulocyte macrophage colony-stimulating factor.
Topics: Alkaloids; Amiloride; Animals; Apoptosis; Bone Marrow; Bone Marrow Cells; Catechols; Cell Division; Cell Line; Cell Survival; DNA; DNA Damage; Fusion Proteins, bcr-abl; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cells; Humans; Hydrogen-Ion Concentration; Interleukin-3; Leukemia, Myeloid, Acute; Nitriles; Protein Kinase Inhibitors; Recombinant Proteins; Staurosporine; Stem Cell Factor; Thymidine; Transfection; Tyrphostins | 1994 |
Differentiation of human myeloblastic leukemia ML-1 cells into macrophages by staurosporine, an inhibitor of protein kinase activities.
Topics: Alkaloids; Cell Differentiation; Cytoplasmic Granules; Histamine; Humans; Leukemia, Myeloid, Acute; Macrophages; Microscopy, Electron; Monocytes; Muramidase; Nitroblue Tetrazolium; Oxidation-Reduction; Protein Kinase Inhibitors; Staining and Labeling; Staurosporine; Tolonium Chloride; Tumor Cells, Cultured | 1993 |
Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells.
Topics: Adult; Aged; Aged, 80 and over; Alkaloids; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Child; Daunorubicin; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Membrane Glycoproteins; Middle Aged; Neoplastic Stem Cells; Protein Kinase C; Rhodamine 123; Rhodamines; Staurosporine; Tumor Cells, Cultured | 1994 |
7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53.
Topics: Adenocarcinoma; Alkaloids; Apoptosis; Caspase 3; Caspases; CDC2 Protein Kinase; Colonic Neoplasms; Cyclin B; Cyclin B1; Cyclins; Cycloheximide; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; DNA Fragmentation; Enzyme Inhibitors; HL-60 Cells; HT29 Cells; Humans; Lamin Type B; Lamins; Leukemia, Myeloid, Acute; Nuclear Proteins; Poly(ADP-ribose) Polymerases; Protein Kinase C; Protein Synthesis Inhibitors; Serine Proteinase Inhibitors; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1997 |
Differentiation induction by a tumor-necrosis-factor mutant 471 in human myelogenous leukemic cells via tumor-necrosis-factor receptor-p55.
Topics: Antigens, CD; Antineoplastic Agents; Cell Differentiation; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase C; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Signal Transduction; Staurosporine; Transduction, Genetic; Tretinoin; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1998 |
S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine.
Topics: Alkaloids; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Leukemia, Myeloid, Acute; S Phase; Staurosporine; Tumor Cells, Cultured | 2001 |